2025. Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s602. DOI:https://doi.org/10.25251/mq5bgn88.